Delphia (USA)’s Revance Therapeutics, Inc. RVNC Stock Holding History

Delphia (USA)’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,881	Closed	-$178K	–	439
2022 Q2	$178K	Buy	+12,881	New	+$198K	0.12%	294

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Delphia (USA)'s RVNC Position: Q3 2022 in Review

Delphia (USA) sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2022, closing a stake of 12,881 shares — an estimated $178K sold.

Delphia (USA) first reported a position in RVNC in Q2 2022 and held it in 1 quarter. The position peaked at $178K in Q2 2022. 182 funds tracked by Wall St. Rank hold RVNC as of Q3 2022.

Delphia (USA) reported no remaining Revance Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
Delphia (USA) sold 12,881 Revance Therapeutics, Inc. shares in Q3 2022, an estimated $178K.
Delphia (USA) first reported a position in Revance Therapeutics, Inc. in Q2 2022 and held it in 1 quarter.
Delphia (USA)'s Revance Therapeutics, Inc. position peaked at $178K in Q2 2022.
182 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.